BioSpace News Archive

Alzamend Neuro, Inc. today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration (“FDA”) for the initiation of study AL001-BD01, a Phase IIA clinical study of AL001 for BD type 1.

Intelligent Bio Solutions Inc. today announced the pricing of an underwritten public offering of units (the “Units”) for gross proceeds of approximately $4.0 million.

Clade Therapeutics today announced that it has completed the acquisition of Gadeta B.V.

NovaBay Pharmaceuticals, Inc. announces that Justin Hall, CEO and General Counsel, will present a company overview and hold investor meetings at the 8th Annual Dawson James Small Cap Growth Conference being held Thursday, October 12, 2023 at the Wyndham Grand Harborside Hotel in Jupiter, Fla.

Nanoscope Therapeutics Inc. is scheduled to participate in the 2023 Ophthalmology Futures Retina Forum and Euretina Innovation Spotlight at the 23rd Euretina Congress, each taking place in Amsterdam, The Netherlands.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company has discontinued the Phase 2b clinical trial of its lead antibiotic candidate, ibezapolstat, for the treatment of patients with Clostridioides difficile infection (CDI) due to success.

BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology, and rare diseases, announced the appointment of Vijay Modur, M.D., Ph.D., as Chief Medical Officer.

Sapio Sciences, the science-aware™ lab informatics platform, announced the release of Sapio Jarvis℠.

Mevion Medical Systems, the leading global provider of compact proton therapy solutions, and RaySearch Laboratories AB, the market leader in software solutions for radiation oncology, are proud to announce their continued commitment to developing new proton therapy solutions.

Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I).